Seegene Rises 7.81% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 18th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.09% compared to the previous day, showing strength, while Seegene, a related stock drawing attention, surged by 7.81% compared to the previous day. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to preliminary data compiled at 11:06, foreigners sold -55,000 shares of Seegene, indicating a large net selling by foreign investors.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Seegene ranked 8th out of 56 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Seegene having relatively high investment attractiveness compared to other stocks in the theme from a financial perspective.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.